शेअर किंमत

Pharmaceuticals company Ind-Swift Laboratories announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations for Q4FY26 was Rs 16,978.68 lakh, showing a growth of 9.86% QoQ from Rs 15,454.37 lakh in Q3FY26 and 19.26% YoY from Rs 14,236.59 लाख Q4FY25 मध्ये. Q4FY26 साठी एकूण उत्पन्न ₹17,200.85 आहे लाख, ₹17,843.21 च्या तुलनेत लाख Q3FY26 मध्ये आणि ₹ 14,205.38 लाख Q4FY25 मध्ये. Consolidated Net Profit for Q4FY26 was Rs 1,511.21 lakh, reflecting a QoQ increase of 58.44% from Rs 953.83 lakh. YoY performance was lower compared to Rs 22,226.88 lakh in Q4FY25 due to high base exceptional gains in the previous year. For the full year ended FY26, consolidated Revenue from Operations was Rs 64,129.31 लाख, ₹57,423.92 पासून 11.68% YoY पर्यंत लाख आर्थिक वर्ष 25 मध्ये. आर्थिक वर्ष 26 साठी एकत्रित निव्वळ नफा ₹4,141.53 होता आर्थिक वर्ष 25 मध्ये ₹25,047.65 लाखांच्या तुलनेत लाख. Consolidated Basic EPS for Q4FY26 was Rs 1.81, compared to Rs 1.17 in Q3FY26 and Rs 33.04 in Q4FY25. Standalone Financial Highlights: Revenue from Operations for Q4FY26 stood at Rs 17,270.06 लाख, जे ₹15,317.14 पासून 12.75% QoQ च्या वाढीचे प्रतिनिधित्व करते लाख Q3FY26 मध्ये आणि वार्षिक 15.50% वाढ ₹ 14,951.76 पासून लाख Q4FY25 मध्ये. Q4FY26 साठी एकूण इन्कम ₹17,491.11 होते लाख, ₹17,705.98 च्या तुलनेत लाख Q3FY26 मध्ये आणि ₹ 14,915.91 लाख Q4FY25 मध्ये. Net Profit for Q4FY26 was Rs 1,493.86 lakh, showing a QoQ increase of 39.07% compared to Rs 1,074.18 लाख Q3FY26 मध्ये. On a YoY basis, it decreased from Rs 21,808.84 lakh in Q4FY25, which was significantly elevated due to a one-time exceptional income gain of Rs 21,587.96 लाख. For the full year ended FY26, standalone Revenue from Operations reached Rs 63,588.85 लाख, ₹ 56,217.34 पेक्षा जास्त 13.11% वाढ लाख आर्थिक वर्ष 25 मध्ये. Standalone Net Profit for FY26 stood at Rs 4,255.68 lakh compared to Rs 25,608.52 लाख आर्थिक वर्ष 25 मध्ये. Standalone Basic Earnings Per Share (EPS) for Q4FY26 was Rs 1.79, compared to Rs 1.32 in Q3FY26 and Rs 32.42 in Q4FY25. Business Highlights: Amalgamation: The company completed the amalgamation of Ind Swift Limited (ISL) with itself during the year. The merger became effective on August 8, 2025, and the results for FY26 represent the combined entity. Segment Performance: The company is exclusively engaged in the Pharmaceutical Business segment. Warrant Conversion: During the year, the company converted 1,95,00,000 warrants into an equivalent number of equity shares. A total of 65,00,000 warrants lapsed due to non-exercise of conversion rights by the allottees, and the upfront amount received was forfeited. Exceptional Items: The company recorded exceptional items (income) of Rs 515.24 lakh for Q4FY26 and Rs 1,100.64 lakh for the full year FY26, primarily related to balances written back or written off on account of amounts no longer payable/receivable. Asset Disposal: The company has entered into an agreement to sell the land and building of its Unit-IV located at Baddi. As of March 31, 2026, the company has received Rs 1,710 lakh as part of the sale consideration. Labour Codes: The company has assessed the impact of the new Labour Codes effective November 21, 2025. Based on actuarial valuation, the estimated impact has been recognized and is not material to the results for the year. Investments: As of March 31, 2026, the company held investments in 800 Non-Convertible Debentures (NCD) of M/s. Ashok Investors Trust Ltd, of which 70 debentures have been redeemed. रिझल्ट PDF

• ट्रेंडलाईन
• 2 आठवडे 4 दिवसांपूर्वी

Pharmaceuticals company Ind-Swift Laboratories announced Q3FY26 results Total Revenue: Rs 177.06 crore against Rs 168.3 crore during Q2FY26, change 5%. EBITDA: Q2FY26 दरम्यान ₹ 8.55 कोटी सापेक्ष ₹ 9.11 कोटी, बदल 7%. EBITDA मार्जिन: Q3FY26 साठी 5.95%. PBT: Q2FY26 दरम्यान ₹ 11.06 कोटी सापेक्ष ₹ 17.61 कोटी, बदल 59%. PAT: Q2FY26 दरम्यान ₹ 8.76 कोटी सापेक्ष ₹ 10.74 कोटी, बदल 23%. PAT मार्जिन: Q3FY26 साठी 6.07%. N.R. Munjal Chairman & Whole Time Director, said: “Revenue remained stable for Q3FY26, while a reduction in raw material and employee benefit expenses drove a 6.60% increase in Operating EBITDA and an Operating EBITDA margin expansion of approximately 48 BPS. This improvement in operational efficiency, translated to a 22.60% rise in Net Profit (PAT) QoQ. Ind-Swift Laboratories Ltd has successfully completed a historic strategic reset through the Rs 1,650 crore divestment of its API & CRAMS business. This decisive action, combined with the merger of Ind-Swift Limited into ISLL, has transformed the company into a Net Debt Free entity with a unified operational structure. Currently, we operate as a Pure-Play Formulations Platform with a solid Revenue base of Rs 550 crore, driven primarily by high-quality exports. The restructuring has consolidated our capabilities across manufacturing, R&D; and distribution, positioning the entire organization for scalable, capitalefficient growth. Further we are accelerating execution across high-growth engines by strengthening CDMO visibility through the FY27 accretive Viatris partnership and expanding our Own-Brand footprint in UAE and Central Asia with 400+ registered products. Supported by high-margin segments like Ethical (76% GM), Own-Brand (51% GM) and CMO (42% GM) we are targeting sustained expansion to Double Revenue by FY29 while delivering consistent profitability.” रिझल्ट PDF

• ट्रेंडलाईन
• 4 महिने 2 आठवड्यांपूर्वी